Tissue Repair & Cytoprotective Research Peptides
Thymosin beta-4
Also known as Tβ4
Last reviewed: 2026-11-19
Evidence status & limitations
Human studies test defined thymosin beta-4 products and endpoints; their results cannot be transferred to an unidentified fragment or material.
Regulatory status
No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Long-term systemic safety and clinical efficacy remain incompletely established.
Key sources
Identity and editorial screen completed November 19, 2026. Previously checked primary references retained; this is not an exhaustive clinical review.
Related compounds
- BPC-157
Same scientific class · A 15-amino-acid chain. · Early human trials
- Thymosin beta-4 fragment (17–23)
Same scientific class · A seven-amino-acid sequence, LKKTETQ, corresponding to residues 17–23 of thymosin beta-4. · Cell/lab studies only